Biogen Inc. (BIIB) drops 6% after mixed Alzheimer’s data
May 14, 20267 min read
Key Takeaway
Biogen Inc. (BIIB) dropped 6.0% after topline Phase 2 CELIA data for diranersen, or BIIB080, showed encouraging biomarker and cognitive signals but missed its primary endpoint on dose response. The market is punishing the mixed readout because it weakens near-term confidence in a high-value Alzheimer’s pipeline asset, even though Biogen still plans to advance the program. For investors, the move underscores that BIIB’s valuation can swing sharply on clinical data despite a stable core business.
Biogen Inc. (BIIB) drops 6.02% today to $192.21 as trading volume runs at 1.7x its 200-day average, a sharp reversal after a volatile session tied to new Alzheimer’s trial data. The move matters because it shows how quickly Wall Street can punish a mixed biotech readout, even when the same data still support a path into late-stage development.
Key Takeaways
BIIB is down 6.02% on above-average volume after Biogen reported topline Phase 2 CELIA data for diranersen, also known as BIIB080, in early Alzheimer’s disease.
The likely catalyst is the market’s negative read on mixed trial results: diranersen missed its primary endpoint on dose response, even though Biogen said the study showed reduced tau pathology and cognitive benefit.
The stock’s reaction looks more company-specific than sector-driven, since healthcare stocks were only modestly softer while BIIB saw a much larger move and heavy trading.
Biogen still has solid near-term financial support, with EPS of 9.31, a P/E near 21.97, and an 8-for-8 earnings beat streak over the last eight quarters.
For investors, today’s selloff highlights a familiar biotech rule: a promising pipeline asset can add upside, but a mixed data set can still cut valuation fast when expectations run ahead of certainty.
Why Biogen Inc. Stock Is Dropping After the Diranersen Alzheimer’s Data
The clearest reason for BIIB’s decline is Thursday’s topline Phase 2 CELIA readout for diranersen. Biogen said the study was the first to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease. However, the same study did not meet its primary endpoint on dose response.
That split result is the heart of the selloff. In biotech, a headline that mixes biological promise with a missed primary endpoint often leads to a hard reset in the stock. Investors do not just buy science. They buy the odds that science can clear the regulatory and commercial bar.
The market had good reason to focus on diranersen. Alzheimer’s is one of the few areas big enough to materially change Biogen’s growth profile. The company already has exposure to the category through LEQEMBI, and diranersen targets tau rather than amyloid. That gave traders a second Alzheimer’s franchise angle to price in before the open. Then reality arrived with more nuance than momentum traders wanted.
That helps explain the intraday whiplash. Reports tied the session directly to the CELIA data, and BIIB traded in a wide range with an intraday high of $225.58 and a low near $192.25. By 14:04 ET, the stock had settled into a 6.02% loss at $192.21.
Above-Average BIIB Volume Shows a Real Catalyst, Not Routine Sector Drift
The volume profile matters here. BIIB traded at 1.7x its 200-day average volume, and market commentary cited roughly 1.91 million shares changing hands versus average daily volume around 1.25 million. That is the footprint of a catalyst day, not a sleepy sector rotation.
Importantly, the broader healthcare tape does not explain the whole move. One market update said healthcare stocks were softer Thursday afternoon, but the NYSE Healthcare Index was only down 0.1%. BIIB’s drop was far larger, which points back to the company-specific trial news.
There was also unusual options activity in BIIB, including a large July 2026 $210 call trade. That kind of flow often shows traders repositioning around a binary event. It does not prove direction on its own, but paired with the volume spike and price swing, it strengthens the case that the CELIA readout drove the action.
Short interest was only around 3% of float, or about 4.4 million shares, so this was not a classic squeeze unwind. Instead, it looks more like the market repriced the asset after deciding the data were not clean enough to support the early optimism.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Biogen Financials Still Look Stable Despite Today’s BIIB Selloff
Today’s drop lands against a steadier financial backdrop than the stock action implies. Biogen has EPS of 9.31 and trades at a P/E of 21.9689, with a market cap of $28.38B. For a large-cap biotech with established neurology and rare disease products, that valuation is not stretched in the way a pure clinical-stage biotech often is.
Earnings execution has also been solid. Biogen has beaten EPS estimates in each of the last eight reported quarters. Most recently, on May 6, 2026, the company posted EPS of $3.57 versus a $3.03 estimate, a 17.8% surprise. Before that, it earned $1.99 versus $1.61 in February and $4.81 versus $3.85 in October 2025.
That streak matters because it shows the core business has not fallen apart while the pipeline story evolves. In plain English, BIIB is not dropping today because the income statement suddenly broke. It is dropping because investors were forced to rethink how much value to assign to a high-profile Alzheimer’s asset.
Analyst sentiment had also been constructive coming into this session. In April, Wells Fargo upgraded BIIB to Overweight, Piper Sandler upgraded it to Overweight, and several firms raised price targets, including RBC Capital to $222 and Guggenheim to $260. The consensus target stands at $211.42, above today’s $192.21 print. That gap shows expectations had improved before the data, which can make a mixed readout sting more.
What the Mixed Alzheimer’s Readout Means for Biogen’s Competitive Position
Strategically, diranersen still matters. Biogen said it plans to advance the program into registrational development based on the biomarker and efficacy signals. That keeps the asset alive and preserves the company’s push to build a deeper Alzheimer’s portfolio beyond LEQEMBI.
Still, Wall Street is drawing a line between scientific interest and investable certainty. A tau-targeting therapy is attractive because it attacks a different disease pathway than amyloid drugs. Yet a missed primary endpoint limits how aggressively investors will capitalize that opportunity today. In other words, the market is willing to pay for progress, but not at full price when the scoreboard is mixed.
Biogen also has other moving parts in the Alzheimer’s business. On May 8, the FDA extended the review period for LEQEMBI IQLIK, the subcutaneous starting-dose formulation, moving the PDUFA date to Aug. 24, 2026. That was a negative update, although it was several days earlier and does not line up as tightly with today’s trading as the CELIA data do.
The broader point is simple. Biogen remains a real player in neurology, but the stock still trades like a company whose future upside depends on pipeline wins. When a major data event lands in the gray zone between breakthrough and miss, the stock often acts like a machine with two gears engaged at once. It jerks before it chooses a direction.
Actionable Take on BIIB After Today’s Sharp Drop
For short-term traders, today’s move confirms that BIIB remains an event-driven stock when Alzheimer’s headlines hit. The wide range, heavy volume, and options activity show that sentiment can swing fast around clinical data.
For longer-term investors, the more useful frame is valuation versus pipeline risk. Biogen still has a profitable base business, a recent pattern of EPS beats, and analyst targets above the latest share price. However, today’s decline shows the market will not give full credit to diranersen until stronger evidence arrives than a mixed Phase 2 result with a missed primary endpoint.
Biogen Inc. (BIIB) drops today because the market is reacting to mixed Phase 2 Alzheimer’s data for diranersen, not because of a broad healthcare washout. The selloff cuts some pipeline premium out of the stock, but it does not erase Biogen’s earnings strength or its strategic position in neurology and Alzheimer’s disease.
BIIB is down because Biogen reported mixed Phase 2 Alzheimer’s data for diranersen, also known as BIIB080. The study showed some positive signals, but it missed its primary endpoint on dose response, which the market viewed negatively.
+Should I buy BIIB stock now?
The stock may appeal to long-term investors who believe Biogen’s core business and Alzheimer’s pipeline can recover from this setback. But the mixed trial result adds risk, so buyers should wait for more clarity on the program and be comfortable with biotech volatility.
+Did Biogen’s Alzheimer’s trial fail completely?
No, the trial did not fail completely. Biogen said the study showed reduced tau pathology and cognitive benefit, but it missed the primary endpoint on dose response, which is why the stock sold off.
+Is today’s BIIB move just a sector selloff?
No, the move looks company-specific rather than sector-wide. Healthcare stocks were only slightly weaker, while BIIB fell much more on heavy volume after the trial update.
Want the full picture on BIIB?
Read the analyst-grade research report — charts, grades, and price targets.
